Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 11 years
- Director since
- 2023
11 years of board service in total across 3 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
Ovid Therapeutics Inc.
Director
Atea Pharmaceuticals Inc.
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Atea Pharmaceuticals Inc. June 18, 202685.6%
-
Ovid Therapeutics Inc. June 6, 202486.8%
-
Atea Pharmaceuticals Inc. June 16, 202371.2%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Atea Pharmaceuticals Inc. | Option exercise | +29,600 | — | — |
| May 5, 2026 | Halozyme Therapeutics Inc. | Grant or award | +3,796 | — | — |
| Jun 20, 2025 | Atea Pharmaceuticals Inc. | Option exercise | +29,600 | — | — |
| May 1, 2025 | Halozyme Therapeutics Inc. | Grant or award | +4,165 | — | — |
| Jun 16, 2024 | Atea Pharmaceuticals Inc. | Option exercise | +33,150 | — | — |
| Apr 25, 2024 | Halozyme Therapeutics Inc. | Grant or award | +6,501 | — | — |
| May 5, 2023 | Halozyme Therapeutics Inc. | Grant or award | +8,065 | — | — |
| Feb 3, 2023 | Halozyme Therapeutics Inc. | Grant or award | +1,188 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.